Antithrombin Supplementation in ECMO

• Status: Completed
• Trial end date: 2019-05-15
• Target enrollment: 0
• Participant gender: All

Summary

Bleeding is the most feared complication during extracorporeal membrane oxygenation (ECMO) and is associated with high dosing of heparin. There is no consensus on antithrombin (AT) supplementation during ECMO. However, AT is needed by heparin to properly anticoagulate. We hypothesize that maintaining normal antithrombin levels during ECMO is associated with a less heparin dosing and more adequate level of anticoagulation.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Policlinico Hospital
• Collaborators: Azienda Ospedaliera Città della Salute e della Scienza di Torino; Azienda Ospedaliera San Gerardo di Monza; The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
• Treatments: Antithrombin III; Antithrombins

Criteria

Inclusion Criteria:

• patients requiring veno-venous ECMO for severe respiratory failure.

Exclusion Criteria:

• patients with pre-existent heparin-induced thrombocytopenia